Skip to Content
Merck
  • Assessment of dengue virus inactivation in random donor platelets using amotosalen and ultraviolet A illumination.

Assessment of dengue virus inactivation in random donor platelets using amotosalen and ultraviolet A illumination.

Asian journal of transfusion science (2022-10-07)
Ankit Kumar, Aseem Kumar Tiwari, Satendra Kumar, Ashutosh Biswas, Gurpreet Singh, Kabita Chatterjee, Sourit Chakroborty, Sujatha Sunil
ABSTRACT

The study objective was evaluation of amotosalen and ultraviolet A (UVA) illumination-based inactivation of dengue virus (DENV) in blood platelets. Whole blood was collected from healthy donors and platelet concentrates were prepared at a tertiary care hospital in Gurugram, India. Platelet units collected from five blood group matched individuals were pooled and spiked with DENV. The spiked platelet units were subjected to amotosalen treatment followed by UVA illumination, to evaluate the efficiency of this method for viral inactivation. The treated platelet units were evaluated for the presence of infectious DENV. Amotosalen levels were quantified in the treated samples using high-performance liquid chromatography. The presence of replicating DENV was not observed in spiked platelet units treated with amotosalen and UVA illumination, whereas untreated units contained actively replicating DENV. Amotosalen levels were found to be in the permissible range after photochemical inactivation. Amotosalen/UVA pathogen inactivation treatment showed efficient inactivation of DENV in platelet components. Therefore, it seems to be a promising method for mitigating the risk of dengue transmission through transfusion of potentially contaminated platelet components in dengue-endemic countries such as India.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-Dengue virus Envelope protein antibody produced in mouse, clone GT643, affinity isolated antibody